AbbVie Gains FDA Approval for Decnupaz in Ultra-Rare Hematologic Malignancy BPDCN

AbbVie's CD123-directed antibody-drug conjugate Decnupaz (pivekimab sunirine-pvzy) cleared FDA approval on May 27, 2026, creating immediate CMC and pharmacovigilance obligations for manufacturers and QA teams handling a conjugate class that carries a Boxed Warning for hepatotoxicity, including hepatic veno-occlusive disease.

The approval covers adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare hematologic malignancy. Efficacy data derive from the CADENZA trial (NCT03386513), a multicenter, open-label, single-arm study. In treatment-naïve patients (N=33), 69.7% achieved complete remission or clinical complete remission (CR/CRc), with a median duration of 9.7 months at 21.5 months follow-up. In relapsed or refractory patients (N=51), the CR/CRc rate was 15.7%, with a median duration of 9.2 months at 24.1 months follow-up.

For manufacturing and QA leads, the conjugate's profile introduces layered GMP complexity. Decnupaz is an alkylating agent conjugate, a payload category that demands stringent containment controls, dedicated or campaign-segregated suites, and validated cleaning procedures under 21 CFR Part 211. The recommended dose of 0.045 mg/kg IV every 21 days, calculated on actual body weight, also places precision compounding and in-process controls at the centre of site readiness planning.

The regulatory pathway is equally instructive for CMC strategy teams. Pivekimab sunirine-pvzy received both breakthrough therapy designation and orphan drug designation, and the application was granted priority review. AbbVie also submitted an Assessment Aid, a voluntary tool that can compress FDA review timelines by pre-organising the benefit-risk framework. For regulatory affairs leads working on rare hematologic programs, this combination of expedited designations alongside a voluntary Assessment Aid submission represents a replicable CMC acceleration model worth benchmarking.

Prescribing information carries additional warnings for infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity, each of which carries downstream implications for risk management plans, label negotiations, and post-marketing pharmacovigilance commitments. Full prescribing information will be posted to Drugs@FDA.

The CADENZA dataset, built on a combined population of 84 patients across treatment-naïve and relapsed/refractory cohorts, will form the evidentiary baseline against which any post-approval safety reporting and label update submissions are measured.